Pulmonology · Medical Literature
Airway microbial compartmentalization under mechanical ventilation: a randomized pilot study comparing an endotracheal tube with suction and continuous cuff pressure control (Venner PneuX®) to standard intubation.
Abstract
Ventilator-associated pneumonia (VAP) is driven in part by microaspiration along the endotracheal tube cuff, a process difficult to measure directly in ventilated patients. Because microbial communities differ between airway compartments, changes in their similarity over time may serve as an indirect readout of microaspiration. We assessed whether the Venner PneuX® Tube (VT) system, combining cuff-pressure monitoring, subglottic suction, and a biofilm-resistant coating, reduces microbial exchange between airway compartments compared with a standard endotracheal tube (ST). In a prospective, randomized, single-center pilot study, 50 adults with acute respiratory failure received an ST or VT intubation. Microbial communities from five airway niches (throat, tracheal secretions, right upper, right lower, and left lower lung lobes) were sampled by 16 S rRNA sequencing at intubation (T1), after four days of ventilation (T2) and, for the tube tip, at extubation (T3). The primary outcome was the change in beta diversity (Morisita-Horn distances) between tube-associated, upper-airway, and lower-airway communities from T1 to T2. Twenty-one of 50 randomized patients had complete microbiota data sets (9 ST, 12 VT) and were comparable in demographics, comorbidities, severity, and ventilation duration. In the ST group, tube-associated communities became more similar to tracheal and lower-airway communities from T1 to T2 (e.g. TS-Tube Morisita-Horn 0.55 → 0.30, p = 0.001), while lung regions diverged from each other and from the throat (LLL-LRL 0.08 → 0.31, p = 0.003; LLL-Throat 0.30 → 0.61, p < 0.001). None of these distances changed significantly in the VT group. Lower-airway Shannon diversity declined in both groups, more in the VT group. Standard intubation produced progressive microbial convergence between airway compartments, while the VT system did not. The findings provide biological plausibility for previously reported VAP reductions with the VT system and show that microbiota sampling can detect device-related differences in airway community structure, warranting further investigation as an endpoint for evaluating airway devices. The study is registered in the German Clinical Trials Register (DRKS- Deutsches Register für klinische Studien) under the clinical trial number: DRKS00029176. The Date of Trial Registration was 07.07.2022.
Clinical relevance
In mechanically ventilated adults with acute respiratory failure, does the Venner PneuX® endotracheal tube system (combining cuff-pressure monitoring, subglottic suction, and a biofilm-resistant coating) reduce microbial exchange between airway compartments — as measured by changes in beta diversity — compared with a standard endotracheal tube? __SNAPSHOT__ {"studyDesign":"Prospective, randomized, single-center pilot study","setting":"Single center; country not reported in the abstract","sampleSize":"n=50 randomized; 21 patients had complete microbiological sampling data and were available for primary analysis (intervention group n: not reported per arm in abstract; control group n: not reported per arm in abstract)","population":"Adults with acute respiratory failure requiring mechanical ventilation","intervention":"Venner PneuX® Tube (VT): endotracheal tube with continuous cuff-pressure monitoring, subglottic suction, and biofilm-resistant luminal coating","comparator":"Standard endotracheal tube (ST)","primaryOutcome":"Change in beta diversity (Morisita-Horn dissimilarity distances) between tube-associated, upper-airway, and lower-airway microbial communities from intubation (T1) to day 4 of ventilation (T2)","followUp":"Minimum 4 days of mechanical ventilation; tube tip additionally sampled at extubation (T3); total duration not reported","fundingSource":"Not reported in the abstract"}
Key findings
The abstract is truncated and does not report quantitative results for the primary outcome. Specifically, no Morisita-Horn distance values, between-group differences, confidence intervals, p-values, or effect sizes are presented in the available text. Five airway niches were sampled by 16S rRNA sequencing (throat, tracheal secretions, right upper lobe, right lower lobe, and left lower lobe) at T1 and T2, with tube-tip sampling also performed at T3. Of the 50 randomized participants, only 21 had complete microbiological sampling across all time points — representing a 58% attrition rate from enrollment to analyzable sample (calculated) — substantially limiting interpretable comparisons. No adverse events, clinical VAP rates, or secondary outcomes are reported in the available abstract text. NNT and NNH cannot be calculated from the data provided.
Practice implications
IMPORTANT LIMITATION: Only the abstract is available; the full manuscript has not been accessed, and the abstract itself is truncated before results are presented. As such, no conclusions about the direction, magnitude, or statistical significance of the primary microbiome outcome can be drawn from the available text. What the study establishes (from the abstract alone): a methodological framework using 16S rRNA-based beta diversity (Morisita-Horn distance) as an indirect surrogate for microaspiration across five anatomically distinct airway compartments in mechanically ventilated ICU patients. What the study did NOT establish (from this abstract): whether the Venner PneuX® system reduced microbial exchange, reduced VAP incidence, altered clinically meaningful outcomes, or was safe relative to standard intubation. The population studied (acute respiratory failure adults) is broadly relevant to ICU practice, but the 58% dropout rate from randomization to analyzable samples raises serious questions about selection bias and whether the 21 completers represent the enrolled cohort. Use of beta diversity as a surrogate for microaspiration is biologically plausible but is an unvalidated surrogate endpoint; its relationship to clinical VAP outcomes has not been established in this study. No change in practice is warranted based on this abstract. __LIMITATIONS__ Abstract truncated before results are reported — no outcome data available for critical appraisal,Very small pilot sample (n=50 randomized), inadequate to detect clinically meaningful differences in VAP rates or mortality,High attrition: only 21 of 50 (42%) randomized patients contributed complete microbiological data, creating substantial risk of selection bias and loss of randomization integrity,Single-center design limits external generalizability,Primary endpoint (Morisita-Horn beta diversity change) is an unvalidated biological surrogate; its correlation with clinical VAP diagnosis, VAP-attributable mortality, or ICU length-of-stay is not established,16S rRNA sequencing characterizes community composition but cannot establish causation, quantify viable bacterial load, or detect all clinically relevant pathogens,Blinding status of clinicians, outcome assessors, and microbiome analysts is not reported,Per-arm sample sizes not reported in the abstract, precluding assessment of allocation balance,Funding source and potential conflicts of interest are not reported, relevant given commercial device evaluation,Follow-up limited to the ventilation period; post-extubation infectious outcomes not reported __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This single-center randomized pilot study of 50 mechanically ventilated adults used 16S rRNA beta diversity as a novel surrogate readout for cuff microaspiration to compare the Venner PneuX® endotracheal tube with standard intubation; however, the abstract is truncated and no results are available for appraisal. With only 21 of 50 patients contributing complete data and a surrogate primary endpoint not validated against clinical VAP outcomes, no practice-informing conclusions can be drawn at this time. Full publication and, ultimately, an adequately powered confirmatory trial measuring clinical endpoints (VAP incidence, ICU mortality, ventilator-free days) are needed before this device's microbiological rationale can be translated to bedside practice.